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ORIGINAL ARTICLE
Diabesity 2017, Volume 3, Number 3: 9-12

A potential role for mTORC1/2 in β2 adrenergic
regulation of skeletal muscle glucose oxidation in
models of intrauterine growth restriction

CrossMark

Robert J. Posont, Caitlin N. Cadaret, Taylor L. Barnes, Dustin T. Yates*
ABSTRACT
The epidemic of intrauterine growth restriction (IUGR) continues to be
a leading cause of perinatal morbidity and mortality throughout the
world. This condition has been linked to the development of metabolic
health problems such as obesity, hypertension, glucose intolerance,
and type 2 diabetes at all ages. Previous studies have demonstrated
that IUGR fetal adaptations impair proper glucose homeostasis in part
via changes in insulin responsiveness in key tissues including skeletal
muscle and liver, and that these deficits persists into adulthood. Many
components of insulin signaling pathways associated with glucose
metabolic regulation have been evaluated in IUGR tissues for adaptive

changes. Among these are mammalian target of rapamycin complexes
1 and 2 (mTORC1/2) and their associated pathways, which function
in mitochondrial control and maintenance. However, recent findings
demonstrate that β2 adrenoceptors (β2AR) appear to activate an insulinindependent pathway or pathways that modify glucose metabolism via
mTORC1/2 complexes. These findings represent a novel potential target
for interventions that could improve the treatment and prevention of
IUGR-induced metabolic disorders. This review will focus on mechanistic
components of β2AR-mTORC1/2 signaling as well as their role in
regulating glucose oxidative metabolism within skeletal muscle.
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INTRODUCTION
Intrauterine growth restriction (IUGR) is characterized by developmental adaptations to chronic
fetal malnutrition that result in asymmetric
growth restriction of skeletal muscle and other
non-visceral soft tissues, regardless of birth weight
percentile (Yates et al., 2012). Indeed, asymmetric growth demarcates this condition from other
non-nutritional causes of small-for-gestational-age
newborns (Sharma et al., 2016). Worldwide, IUGR
affects approximately 30 million pregnancies
each year and the incidence is six-fold greater
in developing countries, well above the internationally-recommended level for initiating public
health actions (de Onis et al., 1998). Studies in
animal models demonstrate that IUGR is a major
predisposing factor for a multitude of postnatal
metabolic complications related to impaired insulin sensitivity and glucose homeostasis (Camacho
et al., 2017). Studies by us and others have demonstrated the ability of β2 adrenoceptors (β2AR) to
regulate glucose metabolism in skeletal muscle
via insulin-independent pathways (Cadaret et al.,
2017; Mukaida et al., 2017; Cipolletta et al., 2017).
Furthermore, Yates et al. (2011) highlighted the
ability of fetal catecholamines to mediate metabolic
adaptations in ovine models of IUGR. Together,
these findings demonstrate the need for a better

understanding of how chronic adrenergic stimulation contributes to the development and progression of IUGR. Recent work in our lab demonstrates
that acute β2 stimulation also acts synergistically
with insulin to enhance stimulation of glucose
oxidation in mature skeletal muscle (Cadaret et al.,
2017). In stark contrast, however, fetal adaptations
to chronically increased catecholamines impair
skeletal muscle insulin responsiveness and reduce
glucose oxidation rates in IUGR fetal and postnatal
muscle (Limesand et al., 2007; Brown et al., 2015;
Camacho et al., 2017). These results demonstrate
that β2-adrenergic and insulin activity can lead to
similar downstream effects on glucose metabolism
via distinctly different pathways that ultimately
converge downstream. One likely site of convergence is the activation of mTORC1 and mTORC2,
which appear to be common downstream targets
for both pathways, as illustrated in Figure 1. Both
mTORC1 and mTORC2 are potent regulators of
glucose uptake when activated by the insulin/
PI3K/PDK1 pathway or inhibited by stress-activated AMPK and TSC pathways (Polak & Hall,
2009). Previous findings indicate that mTORC1/2
also influence mitochondrial oxidation rates and
are activated by insulin-independent increases in
cyclic AMP (cAMP) activity (Cunningham et al.,
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2007; Schieke et al., 2006). Adrenergic regulation of
skeletal muscle and its crosstalk with insulin may
represent novel therapeutic targets for improving
metabolic outcomes in IUGR affected individuals.
In this review, we discuss how these findings relate
to our recent studies, which demonstrate that β2
adrenergic stimulation increases both basal and
insulin-stimulated glucose oxidation rates in skeletal muscle without concurrently increasing glucose
uptake (Cadaret et al., 2017; Merrick et al., 2017).

β2 adrenergic activation of mTORC2
β2 adrenoceptors are G protein-coupled receptors
that primarily activate adenylyl cyclase to increase
production of the second messenger cAMP
(Mukaida et al., 2017). Greater concentrations of
cAMP produced by β2 stimulation lead to activation
of mTORC2 by phosphokinase A (PKA)-mediated
phosphorylation at Ser2481 (Sato et al., 2014). In
turn, mTORC2 then activates Akt via Ser473 phosphorylation (Sato et al., 2014). Not surprisingly,
inhibition of mTORC2 activity leads to decreased
phosphorylation of Akt and a reduction in the
associated downstream effects (Kline et al., 2006;
Sarbassov et al., 2005). This pathway is significant
because it represents a route of Akt activation that
does not require the involvement of PI3K/PDK1,
which activates Akt via phosphorylation at Thr308
(Sato et al., 2014), and demonstrates one potential
mechanism by which β2 adrenergic-mediated pathways lead to the activation of Akt in an insulin-independent manner. Additional comparative studies
demonstrate that inhibition of Akt leads to the loss
of both insulin-mediated and β2 agonist-mediated
effects (Mukaida et al. 2017). This further indicates
that these pathways differ upstream, presumably
at the level of mTORC2, but ultimately converge
at Akt activation. Convergence of the β2/cAMP/
mTORC-mediated pathway with the insulin-PI3K
pathway in skeletal muscle may explain the additive effects of insulin and β2 stimulation on glucose
oxidation by our lab and others (Cadaret et al.,
2017; Scheidegger et al., 1984). These findings also
indicate that mTORC1 is a downstream mediator
of the effects of β2 adrenoceptor activation, as it
is responsive to both Akt and cAMP (Kline et al.,
2006; Kim et al., 2010).
Differential pathways of β2-stimulated
mTORC1 activation
Past studies have shown that Akt and its substrate
PRAS40 are important activators of mTORC1 in
skeletal muscle (Kline et al., 2006; Oshiro et al.,
2007). A subsequent study by Kim et al. (2010) also
demonstrated cAMP to be an indirect promoter
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of mTORC1 activity via its inhibitory action on
PDE4D, a known suppressor of mTORC1. These
parallel pathways (summarized in Figure 1) represent a multi-faceted capacity for β2 adrenergic regulation of mTORC1 via Akt (similarly to insulin),
as well as via a unique Akt-independent PDE4Dmediated pathway. Ultimately, each of these pathways is capable of upregulating activity of the small
GTPase, Rheb, which is a well-characterized activator of mTORC1 (Kim et al., 2010; Oshiro et al.,
2007; Polak and Hall, 2009). Indeed, these findings
would appear to indicate that the two pathways
re-converge upon activating their common hub,
Rheb. Moreover, these parallel pathways offer a
likely explain for how β2 adrenergic stimulation
acts both with and independently of insulin in
regulating skeletal muscle mTORC1 activity and
subsequent glucose oxidation.

mTORC1 mediates mitochondrial oxidative
function
Studies have demonstrated that mTORC1 is a
central metabolic regulator capable of eliciting
rapid changes in cellular metabolism (Cunningham
et al., 2007; Ramanathan and Schreiber, 2009).
Indeed, inhibition of mTORC1 decreases mitochondrial respiration rates in an S6K1/4eBP1independent manner (Ramanathan & Schreiber,
2009). This non-canonical pathway functions via
post-transcriptional co-activation of YY1 and
PGC-1α, which are transcription factors integral
to the control of mitochondrial oxidative metabolism (Cunningham et al., 2007). It is noteworthy
that the effects on mitochondrial function were not
due to changes in overall mitochondrial content in
either of the above studies, further implicating the
acute effects of this pathway. Interestingly, Polak
& Hall (2009) have described how tissue-specific
loss of mTORC1 results in similar phenotypic traits
and metabolic consequences to those observed
in IUGR-born animals (Yates et al., 2011; 2012)
(Figure 2). Collectively, these results indicate that
mTORC1 is a key mediator of the effects of β2 stimulation that we have observed on both basal and
insulin-stimulated glucose oxidation in skeletal
muscle and myoblasts (Cadaret et al., 2017; Merrick
et al., 2017). More importantly, they also indicate
a potential key role for mTORC1 in the metabolic
phenotype associated with IUGR-induced adaptations. Indeed, these mTORC1-mediated pathways
not only provide a mechanistic model for the role
of the β2 adrenergic system in regulation of glucose
homeostasis but may also represent a potential
target for improving metabolic outcomes in IUGRborn individuals.

www.diabesity.ejournals.ca
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Figure 1 Proposed pathways for insulin-dependent and insulin-independent β2 adrenergic regulation of skeletal muscle glucose oxidation.
G protein-coupled β2 adrenoceptors (β2-AR) stimulate adenylyl cyclase (AC) to increase production of cAMP, which sequentially leads to activation of phosphokinase A (PKA), mTORC2,
and Akt. Canonical insulin pathways also activate Akt via PI3K/
mTORC1 and via PDK1. Akt inhibits PRAS40, which directly
increases mTORC1 activity, and inhibits TSC1/2, which indirectly
increases mTORC1 activity by increasing its upstream activator,
Rheb. Greater cAMP production further increases mTORC1 activity by inhibiting the Rheb suppressor, PDE4D. Upon activation,
mTORC1 enters the nucleus, joins co-activators PGC-1 and YY1,
and initiates transcription of genes associated with mitochondrial
oxidative metabolism

oxidation deficits in IUGR skeletal muscle and
thus these pathways represent potential therapeutic targets for metabolic disorders associated with
IUGR. We recently observed that β2 adrenergic
activity enhances both insulin-stimulated and
insulin-independent glucose oxidation in skeletal
muscle and myoblasts without parallel effects on
glucose uptake. We postulate that this is explained
by two parallel β2 adrenergic pathways for Rheb
activation, one involving mTORC2-mediated
activation of Akt and the other resulting from
cAMP-mediated inhibition of the Rheb suppressor, PDE4B. Strikingly similar metabolic deficiencies between IUGR animal models and mTORC1
knockout models make these separate but complimentary pathways for β2 adrenergic enhancement
of Rheb-mediated mTORC1 activity particularly
intriguing as potential therapeutic targets for
IUGR-induced metabolic dysfunction.
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